Difficulty: Medium
Average Score: 81%
Practice
Four patients with chronic low back pain are being considered for treatment with a centrally acting analgesic. Tapentadol is the agent being considered for use. Which of the following challenging patients would best benefit from this agent?
Correct answer
C
Rationale
Tapentadol is a centrally acting analgesic that works by binding to opioid receptors and inhibiting the reuptake of norepinephrine. The patient who would best benefit from this agent among the options provided is the 34-year-old man with renal insufficiency and moderate back pain (Option C).
The correct answer, Option C, is the best choice because tapentadol undergoes hepatic metabolism and does not require renal dose adjustments. In patients with renal insufficiency, drugs that are primarily eliminated through the kidneys may accumulate and lead to toxicity. Therefore, tapentadol is a safer choice for this patient compared to other analgesics.
Option A is incorrect because patients with end-stage liver disease may have impaired drug metabolism and clearance, increasing the risk of adverse effects with tapentadol use.
Option B is incorrect because patients with hepatitis may also have compromised liver function, affecting drug metabolism and increasing the risk of toxicity.
Option D is incorrect because in a patient with metastatic liver cancer to multiple organs, there may be concerns about drug interactions, organ dysfunction, and overall prognosis, making tapentadol a less favorable choice.
In an educational context, understanding the pharmacokinetics and pharmacodynamics of analgesic agents is crucial in selecting the most appropriate treatment for patients with complex medical conditions. Tailoring drug therapy based on individual patient factors such as organ function, comorbidities, and drug interactions is essential for optimizing outcomes and minimizing adverse effects.
The correct answer, Option C, is the best choice because tapentadol undergoes hepatic metabolism and does not require renal dose adjustments. In patients with renal insufficiency, drugs that are primarily eliminated through the kidneys may accumulate and lead to toxicity. Therefore, tapentadol is a safer choice for this patient compared to other analgesics.
Option A is incorrect because patients with end-stage liver disease may have impaired drug metabolism and clearance, increasing the risk of adverse effects with tapentadol use.
Option B is incorrect because patients with hepatitis may also have compromised liver function, affecting drug metabolism and increasing the risk of toxicity.
Option D is incorrect because in a patient with metastatic liver cancer to multiple organs, there may be concerns about drug interactions, organ dysfunction, and overall prognosis, making tapentadol a less favorable choice.
In an educational context, understanding the pharmacokinetics and pharmacodynamics of analgesic agents is crucial in selecting the most appropriate treatment for patients with complex medical conditions. Tailoring drug therapy based on individual patient factors such as organ function, comorbidities, and drug interactions is essential for optimizing outcomes and minimizing adverse effects.